Biogen price target raised to $340-$350 from $300-$304 at Wells Fargo Wells Fargo increased its price target on Biogen as the firm began including revenue from the company's Spinal Muscular Atrophy treatment in its model. Wells keeps a Sector Perform rating on the stock.
News For BIIB From The Last 14 Days
Check below for free stories on BIIB the last two weeks.
Biogen July weekly volatility elevated into Q2 and outlook Biogen July weekly call option implied volatility is at 55, August is at 34, October is at 36; compared to its 26-week average of 33 according to Track Data, suggesting large near term price movement into the expected release of Q2 on July 23.